静脉给予普乐沙福动员异基因外周血干细胞供者可动员出独特移植物
在异基因同胞供者中开展1期后接2期疗效试验,确定静脉普乐沙福最佳剂量为0.32 mg/kg;1次单采采集≥2×10^6 CD34+/kg受者体重的失败率为34%,未达到≤10%的主要终点。研究还发现普乐沙福优先动员一种高干扰素-α产生能力的新型浆细胞样树突状细胞前体,受者CMV病毒血症率15%、急性2-4级GVHD率21%、第100天治疗相关死亡率3%。
要点
- 静脉普乐沙福最佳剂量为0.32 mg/kg,1次单采采集失败率为34%。
- 普乐沙福优先动员高干扰素-α产生能力的新型浆细胞样树突状细胞前体。
- 受者CMV病毒血症率15%、急性2-4级GVHD率21%、第100天治疗相关死亡率3%。
核心结论
- 普乐沙福无论给药途径均可快速动员干细胞,并形成独特的移植物细胞组成和有利的受者结局。
研究设计与样本
- 在异基因同胞供者中开展1期试验后接2期疗效试验,静脉普乐沙福最佳剂量确定为0.32 mg/kg。
主要发现
- 1次单采采集≥2×10^6 CD34+/kg受者体重的失败率为34%,未达到≤10%的主要终点。
- 研究干细胞表型和基因表达发现普乐沙福优先动员一种高干扰素-α产生能力的新型浆细胞样树突状细胞前体。
- 有风险患者的CMV病毒血症率为15%,急性2-4级GVHD率为21%,第100天治疗相关死亡率为3%。
关键数值与推荐
- 静脉普乐沙福最佳剂量为0.32 mg/kg。
- 1次单采采集≥2×10^6 CD34+/kg受者体重的失败率为34%。
- 有风险患者CMV病毒血症率为15%,急性2-4级GVHD率为21%,第100天治疗相关死亡率为3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A single subcutaneous (SC) injection of plerixafor results in rapid mobilization of hematopoietic progenitors, but fails to mobilize 33% of normal allogeneic sibling donors in 1 apheresis. We hypothesized that changing the route of administration of plerixafor from SC to IV may overcome the low stem cell yields and allow collection in 1 day. A phase 1 trial followed by a phase 2 efficacy trial was conducted in allogeneic sibling donors. The optimal dose of IV plerixafor was determined to be 0.32 mg/kg. The primary outcome of reducing the failure to collect ≥2 × 106 CD34+/kg recipient weight in 1 apheresis collection to ≤10% was not reached. The failure rate was 34%. Studies evaluating the stem cell phenotype and gene expression revealed a novel plasmacytoid dendritic cell precursor preferentially mobilized by plerixafor with high interferon-α producing ability. The observed cytomegalovirus (CMV) viremia rate for patients at risk was low (15%), as were the rates of acute grade 2-4 graft-versus-host disease (GVHD) (21%). Day 100 treatment related mortality was low (3%). In conclusion, plerixafor results in rapid stem cell mobilization regardless of route of administration and resulted in novel cellular composition of the graft and favorable recipient outcomes. These trials were registered at clinicaltrials.gov as #NCT00241358 and #NCT00914849.
引用
- Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017. PMID: 28292947. doi:10.1182/blood-2016-09-739722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。